Centro Of Ingegneria Genetica E Biotecnologia Avanzate

Napoli, Italy

Centro Of Ingegneria Genetica E Biotecnologia Avanzate

Napoli, Italy
Time filter
Source Type

Block K.I.,Block Center for Integrative Cancer Treatment | Gyllenhaal C.,Block Center for Integrative Cancer Treatment | Lowe L.,Getting to Know Cancer | Lowe L.,Lancaster University | And 182 more authors.
Seminars in Cancer Biology | Year: 2015

Targeted therapies and the consequent adoption of "personalized" oncology have achieved notablesuccesses in some cancers; however, significant problems remain with this approach. Many targetedtherapies are highly toxic, costs are extremely high, and most patients experience relapse after a fewdisease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistantimmortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are notreliant upon the same mechanisms as those which have been targeted). To address these limitations, aninternational task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspectsof relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a widerange of high-priority targets (74 in total) that could be modified to improve patient outcomes. For thesetargets, corresponding low-toxicity therapeutic approaches were then suggested, many of which werephytochemicals. Proposed actions on each target and all of the approaches were further reviewed forknown effects on other hallmark areas and the tumor microenvironment. Potential contrary or procar-cinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixedevidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of therelationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. Thisnovel approach has potential to be relatively inexpensive, it should help us address stages and types ofcancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for futureresearch is offered. © 2015 The Authors.

Coco S.,Italian National Cancer Institute | Valdora F.,University of Genoa | Bonassi S.,Clinical and Molecular Epidemiology | Scaruffi P.,Centro Fisiopatologia della Riproduzione Umana | And 9 more authors.
OMICS A Journal of Integrative Biology | Year: 2011

Medulloblastoma (MB) is one of the most aggressive pediatric brain tumor. We report genome-wide pooled-analysis of classic MB variant of patients over 3 years of age at diagnosis. We combined array comparative genomic hybridization (aCGH) results from experimental analysis (31 cases) with two public databases (55 cases) in a final evaluation of 86 MBs. The most common chromosome structural aberrations were gains of 17q (45.3%), 1q (22.1%), and losses of 8p (15.1%), 10q (19.8%), 17p (37.2%), and 16q (16.3%). Isochromome (17q) was observed in 29.1% MBs. A significant association between poor patients survival and losses of 9q (p<0.0023), 10q (p<0.012), and 16q (p<0.036) was observed. Univariate analysis showed association of 9q loss (p<0.008) and 16q loss (p=0.05) with adverse overall survival (OS). Chromosome 6 monosomy was a protective event although statistically borderline (p=0.066). After adjusting for confounding factors, a poor OS was found for patients whose tumor has 9q loss [hazard ratio (HR) =3.97; p<0.006) or 16q loss (HR=2.41; p=0.038). Our results highlight the importance of genomic studies in different MB histological variants and indicate a genotype-phenotype correlation. © 2011 Mary Ann Liebert, Inc.

Valdora F.,University of Genoa | Banelli B.,Italian National Cancer Institute | Stigliani S.,Italian National Cancer Institute | Pfister S.M.,German Cancer Research Center | And 16 more authors.
International Journal of Molecular Sciences | Year: 2013

Medulloblastoma (MB) is a malignant pediatric brain tumor arising in the cerebellum consisting of four distinct subgroups: WNT, SHH, Group 3 and Group 4, which exhibit different molecular phenotypes. We studied the expression of Dickkopf (DKK) 1-4 family genes, inhibitors of the Wnt signaling cascade, in MB by screening 355 expression profiles derived from four independent datasets. Upregulation of DKK1, DKK2 and DKK4 mRNA was observed in the WNT subgroup, whereas DKK3 was downregulated in 80% MBs across subgroups with respect to the normal cerebellum (p < 0.001). Since copy number aberrations targeting the DKK3 locus (11p15.3) are rare events, we hypothesized that epigenetic factors could play a role in DKK3 regulation. Accordingly, we studied 77 miRNAs predicting to repress DKK3; however, no significant inverse correlation between miRNA/mRNA expression was observed. Moreover, the low methylation levels in the DKK3 promoters (median: 3%, 5% and 5% for promoter 1, 2 and 3, respectively) excluded the downregulation of gene expression by methylation. On the other hand, the treatment of MB cells with Trichostatin A (TSA), a potent inhibitor of histone deacetylases (HDAC), was able to restore both DKK3 mRNA and protein. In conclusion, DKK3 downregulation across all MB subgroups may be due to epigenetic mechanisms, in particular, through chromatin condensation. © 2013 by the authors; licensee MDPI, Basel, Switzerland.

Coco S.,Italian National Cancer Institute | De Mariano M.,Italian National Cancer Institute | Valdora F.,University of Genoa | Servidei T.,Catholic University | And 5 more authors.
Journal of Human Genetics | Year: 2012

The anaplastic lymphoma kinase (ALK) gene has been found either rearranged or mutated in several neoplasms such as anaplastic large-cell lymphoma, non-small-cell lung cancer, neuroblastoma and anaplastic thyroid cancer. Medulloblastoma (MB) is an embryonic pediatric cancer arising from nervous system, a tissue in which ALK is expressed during embryonic development. We performed an ALK mutation screening in 52 MBs and we found a novel heterozygous germline deletion of a single base in exon 23 (3605delG) in a case with marked anaplasia. This G deletion results in a frameshift mutation producing a premature stop codon in exon 25 of ALK tyrosine kinase domain. We also screened three human MB cell lines without finding any mutation of ALK gene. Quantitative expression analysis of 16 out of 52 samples showed overexpression of ALK mRNA in three MBs. In the present study, we report the first mutation of ALK found in MB. Moreover, a deletion of ALK gene producing a stop codon has not been detected in human tumors up to now. Further investigations are now required to elucidate whether the truncated form of ALK may have a role in signal transduction. © 2012 The Japan Society of Human Genetics All rights reserved.

Andolfo I.,Centro Of Ingegneria Genetica E Biotecnologia Avanzate | Andolfo I.,University of Naples Federico II | Petrosino G.,Centro Of Ingegneria Genetica E Biotecnologia Avanzate | Vecchione L.,The Second University of Naples | And 12 more authors.
BMC Cancer | Year: 2011

Background: Mortality is high in patients with esophageal carcinoma as tumors are rarely detected before the disease has progressed to an advanced stage. Here, we sought to isolate cell-free DNA released into the plasma of patients with esophageal carcinoma, to analyze copy number variations of marker genes in the search for early detection of tumor progression.Methods: Plasma of 41 patients with esophageal carcinoma was prospectively collected before tumor resection and chemotherapy. Our dataset resulted heterogeneous for clinical data, resembling the characteristics of the tumor. DNA from the plasma was extracted to analyze copy number variations of the erbB2 gene using real-time PCR assays.Results: The real-time PCR assays for erbB2 gene showed significant (P = 0.001) copy number variations in the plasma of patients with esophageal carcinoma, as compared to healthy controls with high sensitivity (80%) and specificity (95%). These variations in erbB2 were negatively correlated to the progression free survival of these patients (P = 0.03), and revealed a further risk category stratification of patients with low VEGF expression levels.Conclusion: The copy number variation of erbB2 gene from plasma can be used as prognostic marker for early detection of patients at risk of worse clinical outcome in esophageal cancer. © 2011 Andolfo et al; licensee BioMed Central Ltd.

Loading Centro Of Ingegneria Genetica E Biotecnologia Avanzate collaborators
Loading Centro Of Ingegneria Genetica E Biotecnologia Avanzate collaborators